Highest-materiality recent filing
Ardelyx Q1 revenue $93.4M (+38% YoY); IBSRELA revenue $70.1M (+58% YoY)
Net loss $37.6M ($0.15/sh) vs $41.1M ($0.17/sh) Q1 2025; share-based comp $14.2M.
Ardelyx reports 2025 revenue $407.3M; IBSRELA up 73% to $274.2M; guides 2026 higher
IBSRELA revenue $274.2M in 2025 (+73% YoY); Q4 $86.6M (+61% YoY).
Ardelyx reports preliminary Q4 2025 IBSRELA sales ~$87M, XPHOZAH ~$28M; cash $265M
Preliminary unaudited U.S. net product sales: IBSRELA ~$87M Q4, ~$274M FY 2025.
Ardelyx CLO and CMO resign effective Dec 31; interim CMO appointed
Elizabeth Grammer resigns as Chief Legal and Administrative Officer effective Dec 31, 2025; will serve as General Counsel then Senior Advisor for 24 months.
Ardelyx Q3 2025: product revenue $105.5M, IBSRELA +92% YoY, guidance raised
Total Q3 product revenue $105.5M (+15% YoY); net loss $1.0M ($0.00 per share).
Ardelyx appoints Sue Hohenleitner as CFO
Appointed Sue Hohenleitner as CFO effective Nov 4, 2025; she joins Oct 13, 2025.
Ardelyx Q2 revenue $97.7M (+33%), raises IBSRELA guidance; CFO to depart
Q2 total revenue $97.7M (+33% YoY); IBSRELA net sales $65M (+84% YoY); XPHOZAH net sales $25M (-33% YoY).
Ardelyx draws $50M term loan, secures $100M additional capacity from SLR
Immediate draw of $50.0M (Term E Loan) under Fifth Amendment to 2022 Loan Agreement.
Ardelyx shareholders approve equity plan amendment increasing share reserve by 10M shares
Shareholders approved first amendment to 2014 equity plan, raising authorized shares from 58.5M to 68.5M.
Ardelyx reports Q1 2025 total revenue $74.1M (+61% YoY); IBSRELA $44.4M, XPHOZAH $23.4M
Total revenue $74.1M (+61% YoY); net loss $41.1M ($0.17 loss per share) vs $26.5M loss in Q1 2024.
Ardelyx appoints Merdad Parsey to Board of Directors, effective April 28, 2025
Merdad Parsey, M.D., Ph.D., appointed as Class I director, effective April 28, 2025.
Ardelyx reports FY2024 revenue $333.6M; narrows net loss to $39.1M; provides 2025 guidance
Total revenue $333.6M in 2024, up from $124.5M in 2023; driven by IBSRELA ($158.3M) and XPHOZAH ($160.9M) sales.
Ardelyx reports preliminary Q4 2024 net product sales: IBSRELA $54M, XPHOZAH $57M
IBSRELA net product sales: ~$54M in Q4 2024, ~$158M full year.
Ardelyx appoints Joseph Reilly as Principal Accounting Officer effective Nov 15, 2024
Joseph Reilly, age 51, appointed Principal Accounting Officer, replacing Robert Felsch.
Ardelyx Q3 revenue $98.2M; IBSRELA $40.6M, XPHOZAH $51.5M; net loss $0.8M
IBSRELA Q3 net sales $40.6M (+15% QoQ); full-year guidance set at $145-150M.
Ardelyx signs lease for 15,012 sq ft Newark office; existing Fremont lease amended
Initial 39-month term starting ~Feb 10, 2025; one 60-month extension option.
Ardelyx enters commercial supply agreement with Catalent for IBSRELA through 2028
Agreement covers tableting, testing, release and bulk packaging of IBSRELA (tenapanor HCl) at Catalent's Winchester, KY facility.
Ardelyx Q2 total revenue $73.2M, driven by IBSRELA $35.4M and XPHOZAH $37.1M
IBSRELA Q2 net sales $35.4M, up ~25% QoQ; XPHOZAH Q2 net sales $37.1M, up from $15.2M in Q1 2024.
Ardelyx opts out of CMS TDAPA for XPHOZAH, foregoing add-on payment
Ardelyx will not apply to include XPHOZAH (tenapanor) in CMS ESRD PPS TDAPA program.
Ardelyx shareholders approve amended equity plans at 2024 annual meeting
Stockholders approved amendment and restatement of 2014 Equity Incentive Award Plan (78.3M for, 46.1M against).
Ardelyx CCO Susan Rodriguez resigns; stays in advisory role through 2024
Susan Rodriguez resigned as Chief Commercial Officer on May 22, 2024, by mutual agreement with Ardelyx.
Ardelyx Q1 product revenue $45.6M (IBSRELA $28.4M, XPHOZAH $15.2M); net loss $26.5M
Q1 product-related revenue $45.6M: IBSRELA $28.4M (+149% YoY), XPHOZAH $15.2M (first full quarter after Oct 2023 approval).
On April 28, 2025, the Company appointed Merdad Parsey, M.D., Ph.D, as a member of the Board of Directors (the “Board”) of Ardelyx, Inc., a Delaware corporation (the “Company”), effective immediately
The Company has appointed Joseph Reilly to replace Robert Felsch in his capacity as the Company’s Principal Accounting Officer effective November 15, 2024.
Mr. Felsch will remain with the Company and will transition to a senior financial advisor role within the Company
Max materiality 0.85 · Median 0.68 · Most common event earnings